Skip to main content
. 2021 Nov 15;9(11):1322. doi: 10.3390/vaccines9111322

Table 4.

Adherence to the SAGER Guidelines by the six main Phase II/III and Phase III trials in our sample.

Name of Vaccine
(Ref.)
Phase Introduction Methodology Sex Disaggregation Discussion Generalizability No. of Doses *
CoronaVac [59] III No No No No No 367 million
AstraZeneca ** [60] II/III No No No No No 3009 million
Sputnik V [28] III No No Yes (immunogenicity) No No 765 million
Moderna [29] III No No Yes (efficacy) No No 816 million
Pfizer-BioNTech [24] III No No Yes (efficacy) No Yes 1220 million
Janssen [16] III No No Yes (efficacy) No No 368 million

** Number of doses ordered as of 28 May 2021 based on data from Statistica (59); * Phase III AstraZeneca paper yet to be published as of 22 April 2021 when our search was conducted.